2018 Press Releases

2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015


November 30, 2018

Eureka Therapeutics Announces Data Presentations Validating its Proprietary E-ALPHA Discovery Platform at the 2018 ASH Annual Meeting

November 21, 2018

Eureka Therapeutics Announces Publication of Preclinical Study Validating its ARTEMIS Platform Designed to Mitigate the Risk of Cytokine Release Syndrome (CRS) and Neurotoxicity

September 5, 2018

Eureka Therapeutics Achieves Regression of Metastatic Liver Cancer using ET140202 T-cell Therapy

August 30, 2018

Eureka Therapeutics to Present Proof-of-Concept Preliminary Data from Ongoing China Clinical Study of ET140202 at CAR-TCR 2018 Summit

August 16, 2018

Eureka Therapeutics Announces Publication of Armored T-Cell Proof-of-Concept Study in Nature Biotechnology

July 17, 2018

Eureka Therapeutics Announces that Boehringer Ingelheim is Exercising an Option to License Novel TCR Mimic (TCRm) Antibodies

July 16, 2018

Eureka Expands Scientific Advisory Board Members with Addition of Cytokine Release Syndrome (CRS) Experts Stephan A. Grupp, M.D., Ph.D. and Cameron J. Turtle, MBBS, Ph.D., FRACP, FRCPA

June 4, 2018

Eureka Therapeutics Announces Positive Preliminary Results Of ET190L1 ARTEMIS™ T-Cell China Proof-Of-Concept Human Clinical Study In Relapsed And Refractory B-Cell Lymphoma At ASCO Annual Meeting

January 22, 2018

Eureka Therapeutics Closes $60 Million in Series D Financing to Advance Proprietary ARTEMIS™ T Cell Receptor Platform for Safer T Cell Therapies